What's new on giant cell tumor of bone.

IF 2.3 Q2 ORTHOPEDICS
SICOT-J Pub Date : 2026-01-01 Epub Date: 2026-01-22 DOI:10.1051/sicotj/2025063
Shinji Tsukamoto, Costantino Errani, Tessa Balach, Tomas Zamora, Eduardo Ortiz-Cruz, Raja Bhaskara Rajasekaran, Raymond Yau, Tao Ji, Israel Pérez-Muñoz, Francisco Linares, Andrea Angelini, Pietro Ruggieri, Joseph Benevenia, Andreas F Mavrogenis
{"title":"What's new on giant cell tumor of bone.","authors":"Shinji Tsukamoto, Costantino Errani, Tessa Balach, Tomas Zamora, Eduardo Ortiz-Cruz, Raja Bhaskara Rajasekaran, Raymond Yau, Tao Ji, Israel Pérez-Muñoz, Francisco Linares, Andrea Angelini, Pietro Ruggieri, Joseph Benevenia, Andreas F Mavrogenis","doi":"10.1051/sicotj/2025063","DOIUrl":null,"url":null,"abstract":"<p><p>When treating extremities affected by giant cell tumor of bone (GCTB), curettage should be performed to preserve the joint as much as possible in order to obtain a good functional outcome. The local recurrence risk is high following curettage, but new techniques are being developed to reduce local recurrence. We present a review of the literature reporting favorable results of radiofrequency ablation alone in locally recurrent small GCTB. New filling materials are also being developed to prevent non-oncological complications such as arthrosis and fractures. Routine measurement of tartrate-resistant acid phosphatase 5b in serum may be helpful in detecting early instances of local recurrence. For unresectable or metastatic GCTB, there is an urgent need for a new drug that is as effective as denosumab, avoids side effects, and can be administered to pregnant women.</p>","PeriodicalId":46378,"journal":{"name":"SICOT-J","volume":"12 ","pages":"2"},"PeriodicalIF":2.3000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12825416/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SICOT-J","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1051/sicotj/2025063","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0

Abstract

When treating extremities affected by giant cell tumor of bone (GCTB), curettage should be performed to preserve the joint as much as possible in order to obtain a good functional outcome. The local recurrence risk is high following curettage, but new techniques are being developed to reduce local recurrence. We present a review of the literature reporting favorable results of radiofrequency ablation alone in locally recurrent small GCTB. New filling materials are also being developed to prevent non-oncological complications such as arthrosis and fractures. Routine measurement of tartrate-resistant acid phosphatase 5b in serum may be helpful in detecting early instances of local recurrence. For unresectable or metastatic GCTB, there is an urgent need for a new drug that is as effective as denosumab, avoids side effects, and can be administered to pregnant women.

骨巨细胞瘤有什么新进展?
在治疗骨巨细胞瘤(GCTB)影响的肢体时,应尽可能进行刮除以保留关节,以获得良好的功能结果。刮除后局部复发的风险很高,但正在开发新的技术来减少局部复发。我们回顾了文献报道的射频消融治疗局部复发小GCTB的良好结果。新的填充材料也正在开发,以防止非肿瘤并发症,如关节和骨折。常规测定血清中酒石酸盐抗性酸性磷酸酶5b可能有助于发现局部复发的早期病例。对于不可切除或转移性的GCTB,迫切需要一种与denosumab一样有效、避免副作用并可用于孕妇的新药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
SICOT-J
SICOT-J ORTHOPEDICS-
CiteScore
3.20
自引率
12.50%
发文量
44
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书